{"id":29339,"date":"2015-12-01T12:05:16","date_gmt":"2015-12-01T12:05:16","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29339"},"modified":"2016-02-29T15:43:22","modified_gmt":"2016-02-29T15:43:22","slug":"nice-decision-on-ledipasvirsofosbuvir-for-chronic-hcv","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29339","title":{"rendered":"NICE decision on ledipasvir\/sofosbuvir for chronic HCV"},"content":{"rendered":"<p><strong>On 25 November, NICE published guidance for the limited use of sofosbuvir\/ledipasvir for chronic hepatitis C (HCV).<\/strong> [1]<\/p>\n<p>As with the NICE approach to other new direct acting antivirals DAAs), the recommendation are categorised both by genotype and treatment experience, see Table 1.<\/p>\n<p>For full details of the guidelines are available online.<\/p>\n<p>NHS treatment with ledipasvir\/sofosbuvir should be available within three months of this decision.<\/p>\n<p>The coformulation of ledipasvir.sofosbuvir is manufacture by Gilead Sciences and marketed under the tradename Harvoni.<\/p>\n<table border=\"0\">\n<caption>Table 1: Summary of NICE recommendation for ledipasvir\/sofosbuvir<\/caption>\n<tbody>\n<tr>\n<th colspan=\"2\" scope=\"col\">HCV treatment-naive patients<\/th>\n<\/tr>\n<tr>\n<td>G1 without cirrhosis<\/td>\n<td>8 weeks treatment<\/td>\n<\/tr>\n<tr>\n<td>G1 or G4 with cirrhosis<\/td>\n<td>12 weeks treatment<\/td>\n<\/tr>\n<tr>\n<th colspan=\"2\" scope=\"col\">HCV treatment-experienced patients<\/th>\n<\/tr>\n<tr>\n<td>G1 or G4 without cirrhosis<\/td>\n<td>12 weeks treatment<\/td>\n<\/tr>\n<tr>\n<td>G1 or G4 with cirrhosis<\/td>\n<td>12 weeks treatment, but only if there is a low risk of disease progression<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Comment<\/h3>\n<p><strong>A price for ledipasvir\/sofosbuvir is approximately \u00a326,000 for 8-weeks and \u00a338,000 for 12-weeks of treatment, both excluding VAT.<\/strong><\/p>\n<p><strong>The guidance notes that a nationally available price reduction for ledipasvir\/sofosbuvir has been agreed with the Commercial Medicines Unit, but also that this was not considered as part of the submission. No details of the reduced price have been published.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>NICE. Ledipasvir\u2013sofosbuvir for treating chronic hepatitis C. NICE technology appraisals [TA363]. (25 November 2015)<br \/>\n<a href=\"http:\/\/www.nice.org.uk\/guidance\/ta363\">http:\/\/www.nice.org.uk\/guidance\/ta363<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 25 November, NICE published guidance for the limited use of sofosbuvir\/ledipasvir for chronic hepatitis C (HCV). [1] As with the NICE approach to other new direct acting antivirals DAAs), the recommendation are categorised both by genotype and treatment experience, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-29339","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29339"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29339\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}